These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 26378119)

  • 21. Coding of information in limit cycle oscillators.
    Schleimer JH; Stemmler M
    Phys Rev Lett; 2009 Dec; 103(24):248105. PubMed ID: 20366234
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Symmetry structure in discrete models of biochemical systems: natural subsystems and the weak control hierarchy in a new model of computation driven by interactions.
    Nehaniv CL; Rhodes J; Egri-Nagy A; Dini P; Morris ER; Horváth G; Karimi F; Schreckling D; Schilstra MJ
    Philos Trans A Math Phys Eng Sci; 2015 Jul; 373(2046):. PubMed ID: 26078349
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Mathematical modeling of functioning of the p53-Mdm2 protein system.
    Voropaeva OF; Shokin YI; Nepomnyashchikh LM; Senchukova SR
    Bull Exp Biol Med; 2014 Jun; 157(2):291-4. PubMed ID: 24952502
    [TBL] [Abstract][Full Text] [Related]  

  • 24. TAp73 alpha increases p53 tumor suppressor activity in thyroid cancer cells via the inhibition of Mdm2-mediated degradation.
    Malaguarnera R; Vella V; Pandini G; Sanfilippo M; Pezzino V; Vigneri R; Frasca F
    Mol Cancer Res; 2008 Jan; 6(1):64-77. PubMed ID: 18234963
    [TBL] [Abstract][Full Text] [Related]  

  • 25. UBTD1 induces cellular senescence through an UBTD1-Mdm2/p53 positive feedback loop.
    Zhang XW; Wang XF; Ni SJ; Qin W; Zhao LQ; Hua RX; Lu YW; Li J; Dimri GP; Guo WJ
    J Pathol; 2015 Mar; 235(4):656-67. PubMed ID: 25382750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mdm2 is required for inhibition of Cdk2 activity by p21, thereby contributing to p53-dependent cell cycle arrest.
    Giono LE; Manfredi JJ
    Mol Cell Biol; 2007 Jun; 27(11):4166-78. PubMed ID: 17371838
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dynamical principles of two-component genetic oscillators.
    Guantes R; Poyatos JF
    PLoS Comput Biol; 2006 Mar; 2(3):e30. PubMed ID: 16604190
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HAUSP-regulated switch from auto- to p53 ubiquitination by Mdm2 (in silico discovery).
    Brazhnik P; Kohn KW
    Math Biosci; 2007 Nov; 210(1):60-77. PubMed ID: 17585950
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The MDM4/MDM2-p53-IGF1 axis controls axonal regeneration, sprouting and functional recovery after CNS injury.
    Joshi Y; Sória MG; Quadrato G; Inak G; Zhou L; Hervera A; Rathore KI; Elnaggar M; Cucchiarini M; Marine JC; Puttagunta R; Di Giovanni S
    Brain; 2015 Jul; 138(Pt 7):1843-62. PubMed ID: 25981963
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Development of E3-substrate (MDM2-p53)-binding inhibitors: structural aspects.
    Fry DC; Graves B; Vassilev LT
    Methods Enzymol; 2005; 399():622-33. PubMed ID: 16338385
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Quantitative assessment of the p53-Mdm2 feedback loop using protein lysate microarrays.
    Ramalingam S; Honkanen P; Young L; Shimura T; Austin J; Steeg PS; Nishizuka S
    Cancer Res; 2007 Jul; 67(13):6247-52. PubMed ID: 17616682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
    Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
    Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Small-molecule inhibitors of the p53-MDM2 interaction.
    Vu BT; Vassilev L
    Curr Top Microbiol Immunol; 2011; 348():151-72. PubMed ID: 21046355
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Small-molecule MDM2 antagonists reveal aberrant p53 signaling in cancer: implications for therapy.
    Tovar C; Rosinski J; Filipovic Z; Higgins B; Kolinsky K; Hilton H; Zhao X; Vu BT; Qing W; Packman K; Myklebost O; Heimbrook DC; Vassilev LT
    Proc Natl Acad Sci U S A; 2006 Feb; 103(6):1888-93. PubMed ID: 16443686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers.
    Abdel-Fatah TM; Powe DG; Agboola J; Adamowicz-Brice M; Blamey RW; Lopez-Garcia MA; Green AR; Reis-Filho JS; Ellis IO
    J Pathol; 2010 Mar; 220(4):419-34. PubMed ID: 20044801
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The MDM2 ubiquitination signal in the DNA-binding domain of p53 forms a docking site for calcium calmodulin kinase superfamily members.
    Craig AL; Chrystal JA; Fraser JA; Sphyris N; Lin Y; Harrison BJ; Scott MT; Dornreiter I; Hupp TR
    Mol Cell Biol; 2007 May; 27(9):3542-55. PubMed ID: 17339337
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genetdes: automatic design of transcriptional networks.
    Rodrigo G; Carrera J; Jaramillo A
    Bioinformatics; 2007 Jul; 23(14):1857-8. PubMed ID: 17485427
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of dendritic load on the firing frequency of oscillating neurons.
    Schwemmer MA; Lewis TJ
    Phys Rev E Stat Nonlin Soft Matter Phys; 2011 Mar; 83(3 Pt 1):031906. PubMed ID: 21517524
    [TBL] [Abstract][Full Text] [Related]  

  • 39. p53 mediates the negative regulation of MDM2 by orphan receptor TR3.
    Zhao BX; Chen HZ; Lei NZ; Li GD; Zhao WX; Zhan YY; Liu B; Lin SC; Wu Q
    EMBO J; 2006 Dec; 25(24):5703-15. PubMed ID: 17139261
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel MDM2 p53-independent functions identified through RNA silencing technologies.
    Zhang Z; Wang H; Li M; Rayburn E; Agrawal S; Zhang R
    Ann N Y Acad Sci; 2005 Nov; 1058():205-14. PubMed ID: 16394138
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.